Dr. G Lyman has acted as a speaker for Amgen, Inc. (Thousand Oaks, CA) and receives research support from Amgen. Dr. J Glaspy receives research support from Amgen, Inc.
Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia?
A systematic review
Article first published online: 5 DEC 2005
Copyright © 2005 American Cancer Society
Volume 106, Issue 1, pages 223–233, 1 January 2006
How to Cite
Lyman, G. H. and Glaspy, J. (2006), Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia?. Cancer, 106: 223–233. doi: 10.1002/cncr.21570
- Issue published online: 23 DEC 2005
- Article first published online: 5 DEC 2005
- Manuscript Accepted: 16 JUL 2005
- Manuscript Revised: 24 JUN 2005
- Manuscript Received: 29 MAR 2005
- 3Cancer Therapy Evaluation Program (CTEP). Common toxicity criteria, v. 2.0. DCTD, NCI, HIH, DHHS. March 1998. Available from URL: http://www.fda.gov/cder/cancer/toxicityframe.htm. [Accessed February 2004].
- 4Food and Drug Administration/Center for Drug Evaluation and Research Oncology Tools page. World Health Organization toxicity criteria. Food and Drug Administration Web site. Available from URL: http://www.fda.gov/cder/cancer/toxicityframe.htm. [Accessed February 2004].
- 16Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1964; 58: 163–170..
- 24Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003; 64: 102–110., , , et al.
- 27Caradian Eprex Study Group. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy [presentation]. 2003 ASCO Annual Meeting. Available from URL: http://media.asco.org/asco/meetings_education/vm/2003/slides_only/2003/2309/PPT/01.gif. [Accessed March 2004]., , for the
- 28http://media.asco.org/asco/meetings_education/vm/2003/slides_only/frame.asp?ID=2055. [Accessed March 2004]., , , , . Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy [presentation]. 2003 ASCO Annual Meeting. Available from URL:
- 29http://www.asco.org/ac/1,1003,_12-002643-00_18-0026-00_19-002479,00.asp. [Accessed July 2004]., , , et al. Results of a randomized study of every-three week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anemia (CIA) [presentation]. 2004 ASCO Annual Meeting. Available from URL:
- 30http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-009068,00.asp. [Accessed July 2004]., , , . Early intervention with epoetin-alfa during platinum-based chemotherapy [presentation]. 2004 ASCO Annual Meeting. Available from URL:
- 31Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life outcomes in anemia cancer patients undergoing chemotherapy [abstract 3524]. Blood. 2002; 100: 18b., .
- 35RodgersGM, editor. Guidelines for supportive care: cancer and treatment-related anemia. v.2.2004 ed: National Comprehensive Cancer Network. Available from URL: http://www.nccn.org/physician_gls/index.html [accessed March 24, 2005].